New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Lexaria Bioscience Corp. (LEXX) vs Lisata Therapeutics, Inc. (LSTA)
- Lexaria Bioscience Corp. LEXX 4.03 −10.24%
- Lisata Therapeutics, Inc. LSTA 0.90 −1.10%
Lexaria Bioscience Corp. and Lisata Therapeutics, Inc. are both Biotechnology companies. Lexaria Bioscience Corp. and Lisata Therapeutics, Inc. are of similar size ($9.8M and $9.5M). Lisata Therapeutics, Inc. grew revenue faster over the last twelve months: 57.2% against 52.0%. Lisata Therapeutics, Inc. has the higher net margin (−274.9% vs −1,686.1%) and the higher return on invested capital (0.00% vs −662.6%). Across the 16 metrics below, Lisata Therapeutics, Inc. leads on 12 and Lexaria Bioscience Corp. on 4.
Valuation
Profitability
| Metric | LEXX | LSTA | Biotechnology median |
|---|---|---|---|
| Gross margin | 99.62% | 14.13% | 70.18% |
| Operating margin | (1,683.06%) | (398.56%) | 0.00% |
| Net margin | (1,686.05%) | (274.88%) | 0.00% |
| Free cash flow margin | (1,494.56%) | (137.78%) | 0.00% |
| Return on equity | (162.60%) | (138.59%) | (51.58%) |
| Return on assets | (134.20%) | (5.12%) | (45.91%) |
| Return on invested capital | (662.56%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack